Scholarly article on topic 'Thioxopyrimidine in Heterocyclic Synthesis I: Synthesis of Some Novel 6-(Heteroatom-substituted)-(thio)pyrimidine Derivatives'

Thioxopyrimidine in Heterocyclic Synthesis I: Synthesis of Some Novel 6-(Heteroatom-substituted)-(thio)pyrimidine Derivatives Academic research paper on "Chemical sciences"

CC BY
0
0
Share paper
Academic journal
Journal of Chemistry
OECD Field of science
Keywords
{""}

Academic research paper on topic "Thioxopyrimidine in Heterocyclic Synthesis I: Synthesis of Some Novel 6-(Heteroatom-substituted)-(thio)pyrimidine Derivatives"

Hindawi Publishing Corporation

Journal of Chemistry

Volume 2013, Article ID 765243, 15 pages

http://dx.doi.org/10.1155/2013/765243

Research Article

Thioxopyrimidine in Heterocyclic Synthesis I: Synthesis of Some Novel 6-(Heteroatom-substituted)-(thio)pyrimidine Derivatives

Yuh-Wen Ho and Maw Cherng Suen

Department of Creative Fashion Design, Taoyuan Innovation Institute of Technology, Jhongli 32091, Taiwan Correspondence should be addressed to Yuh-Wen Ho; wen@tiit.edu.tw Received 27 June 2012; Revised 30 August 2012; Accepted 16 October 2012 Academic Editor: Filomena Conforti

Copyright © 2013 Y.-W. Ho and M. C. Suen. "ttis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A series of novel N-cycloalkanes, morpholine, piperazines, pyrazole, pyrimidine, benzimidazolo[1,2-a]pyrimidine, 1,2,3,4-tetrazolo[1,5-a]pyrimidine, azopyrazolo[1,5- a]pyrimidine, pyrimido[4', 5' :3,4]pyrazolo[1,5-a]pyrimidines and pyridine derivatives incorporating a 5-cyano-4-methyl-2-phenyl-(thio)pyrimidine moiety were obtained by the intramolecular cyclization of 6-methylthio-pyrimidine, 6-(benzoylmethyl)thio- pyrimidine and 2-[(5-cyano-4-methyl-2-phenylpyrimidin-6-yl)thio]-3-dimethyl-amino-1-phenyl-prop-2-en-1-one with appropriate amines and enaminone compounds, respectively. "tte structure of all new synthesized compounds was established from their spectral data, elemental analysis and the X-ray crystal analysis.

1. Introduction

Pyrimidine derivatives attracted organic chemists very much due to their biological and chemotherapeutic importance. Pyrimidine derivatives and related fused heterocycles are important classes of heterocyclic compounds that exhibit a broad spectrum of biological activities such as anticancer [15], antiviral [6], antibacterial [7, 8], antioxidant [9, 10], anxiolytic [11], and antidepressant activities [12]. Furthermore, they possess anti-inflammatory [13-19] and analgesic activities that are well documented in the literature [20-22]. tte incorporation of two moieties increases biological activity of both and thus it was of value to synthesize some new hetero-cyclic derivatives having two moieties in the same molecules. tte course of our researches was devoted to the development of new classes of pyrimidines substituted at position-6 with different fused heterocycles moiety in the hope that they may be biologically active. In preceding papers [23-25] we have described the synthesis of a series of novel 5-(1-pyrrolyl)-4-methyl-2-phenylthieno[2,3-d]pyrimidine derivatives containing chalcones, pyridines, pyridin-2(1H)-ones, 2H-pyran-2-one, pyrazoles, pyrimidines imidazolpyrimidines, pyrazolopyrimidines, and 1,3,4-oxadiazoles moiety. In continuation of our studies, we report herein the use of

thioxopyrimidine 1 for the synthesis of various N-cyclo-alkanes, morpholine, piperazines, pyridines, pyrazole, pyrimidine, benzimidazolo[1,5-a]pyrimidine, 1,2,3,4-tetrazolo [1,5-a]pyrimidine, azopyrazolo[1,5-a]pyrimidine, and pyri-mido[4 ,5 :3,4]pyrazolo[1,5-a]pyrimidine incorporating a (thio)pyrimidine moiety. tte structure of the new compounds was verified by spectroscopic methods and the X-ray crystal structure of compound 13 is also discussed.

2. Experimental

All melting points are uncorrected and in °C. IR spectra were recorded on a JASCO FTIR-3 spectrometer (KBr); *H-NMR spectra were obtained on a Bruker AM-300 WB FI-NLR spectrometer, and chemical shifts are expressed in S ppm using TMS as an internal standard. Electron impact mass spectra were obtained at 70 eV using a Finingan Mat TSQ-46C spectrometer. Microanalyses for C, H, and N were performed on a Perkin-Elmer 240 elemental Analyzer. Enaminone derivatives 14a-f, 5-amino-4-phenylazo-3-methyl-1H-pyrazole 26, and 3-amino-4-methyl-6-phenyl-pyrazolo-[3,4-d]pyrimidine 28 were prepared following the methods in the literature [24, 26,27].

2.69 (3H, s)

CN 4.16 (4H, d)

•j, /— 4.02 (4H, d)

8.42-8.4,

7.51-7.45 (5H, m)

6.56 (1H, m)

8.36 (2H, d)

Figure 1: Structural assignment of typical protons in 5f by 'HNMR.

c(i8) je^" ~)C(16)

Figure 2: Perspective view of compound 13 with atomic numbering.

2.1. 5-Cyano-1,6-dihydro-4-methyl-2-phenyl-6-thioxopyri-midine (1). To a suspension of ammonium thiocyanate (7.60 g, 0.1 mol) in dry dioxane (100 mL), benzoyl chloride (14 g, 0.1 mol) was added. tte reaction mixture was refluxed for 5 min., then treated with 3-aminocrotononitrile (8.20 g, 0.1 mol). tte reaction mixture was refluxed for 2h and poured into ice water. tte solid product was collected by filtration, washed with water, and recrystallized from ethanol to give 17 g of yellow needle crystals (74% yield), mp 212°C; IR: v 2225 (CN), 1200 (C=S) cm-1; JH-NMR (DMSO-d6): 5 2.50 (3H, s, CH3), 2.90 (1H, s, NH), 7.66-7.51, 8.11-8.08 (5H, m, phenyl-H); m/z: 227 (M+). Anal. Calcd. for C12H9N3S: C, 63.43; H, 3.96; N, 18.50. Found: C, 63.40; H, 4.00;N, 18.60%.

2.2. 5-Cyano-4-methyl-2-phenyl-6-methylthio-pyrimidine (2). A mixture of compound 1 (0.23 g, 1 mmol) in methanol (10 mL) and sodium methoxide (0.08 g, 1.5 mmol) and methyl iodide (0.17 g, 1.2mmol) were added. After stirring at room temperature for 4 h, the resulting solid product was collected by filtration, washed with water, and recrystallized

from THF to give 0.21 g of pale yellow crystals (87% yield), mp 144°C; IR: v 2207 (C=N) cm-1; 1H-NMR (CDCl3): S 2.70 (3H, s, CH3), 2.75 (3H, s, SCH3), 8.49-8.47, 7.55-73.49 (5H, m, phenyl-H); MS (m/z, %): 241(M+,100), 227(4), 195(4), 153(14), 138(9), 111(3), 104(17), 244(2), 77(10), 51(6). Anal. Calcd. for C13H11N3S: C, 64.73; H, 4.56; N, 17.42. Found: C, 64.88 H, 4.54; N, 17.55%.

2.3. 5-Cyano-4-formyl-2-phenyl-6-methylthio-pyrimidine (3). A mixture of 5-cyano-4-methyl-2-phenyl-6-methylthio-py-rimidine 2 (0.24 g, 1 mmol) and selenium oxide (0.11 g, 1 mmol) in dioxane (10 mL) was refluxed for 1 h. After cooling, the mixture was filtered. tte filtrate was evaporated under reduced pressure, and the resulting residue was purified by column chromatography (light petroleum ether/ethyl acetate 7: 3 v/v as eluent) to give 0.2 g of reddish brown needles (78% yield), mp 164°C; IR: v 2218 (C=N), 1689 (C=O) cm-1; 1H-NMR (DMSO-d6): S 2.74 (3H, s, SCH3), 8.40, 7.61-7.52 (5H, m, phenyl-H), 9.85 (1H, s, CHO); MS (m/z, %): 255(M+, 18), 241(100), 277(61), 200(22), 138(10),

(CH3)2N^J^CH=CH ^^-"^N CN

S CH30Na

|| i "N sch3 "" 2

NH2NHCO

N -NHNHCO

(CH3 )2 ,vcho

Dioxane/piperidine 4b CH3

H"0 )„

CN NN 4a, b

)» n = 1,2

dioxane

| J N SCH3 3

H—N X

5a-f: X = O, N-CH3, N-C2H5, N-COOC2H5

N-C6H5, N-pyrimidinyl

Scheme 1

104(12), 97(5). Anal. Calcd. for C13H9N3OS: C, 61.17; H, 3.52; N, 16.47. Found: C, 61.13; H, 3.72; N, 16.45%.

2.4. 6-Substituted-5-cyano-4-methyl-2-phenyl-pyrimidine Derivatives (4a,b and 5a-f) General Procedure. A mixture of compound 2 (0.24 g, 1 mmol) and excess secondary amines (pyrrolidine, piperidine, morpholine, N-methylpiperazine,

N-ethylpiperazine, ethyl 1-piperazinecarboxylate, 1-phenyl-piperazine, and 1-(2-pyrimidyl)piperazine) (5 mmol) was refluxed for 10 h and poured into ice-water, and the precipitated product was collected by filtration, washed with water, and the crude product recrystallized from chloroform/THF. ^e physical constants and spectral data of compounds 4a,b and 5a-f are recorded in Tables 1 and 2.

H I %^-S(CH2)3CN

2 C2 H5ON Room

temperature

2, 5-dimethoxy-tetrahydrofuran

Cl(CH2 )3CN

CH3COOH reflux

DMF/ 2 C2H5ON

BrCH2CO-(^) —

temperature

ÇH JN

CH3 NH2

NaN3 reflux

HC(OEt)3 (CH3CO)2O

DMF/ 1 C2H5ONa

temperature

çH N^

* CMsch2COO

Scheme 2

Table 1: Physical and analytical data of 6-substituted-pyrimidine derivatives (4a, b and 5a-f).

Compd.

M.P. (°C)a Yield (%) Molecular formula

Elemental Analysis (%) Calcd/Found.

154 89 C^H^N« 72.72 6.06 21.21

72.79 6.01 21.24

111 88 C17H18N4 73.38 6.47 20.14

73.41 6.51 20.11

178 79 C16H16N4O 68.57 5.71 20.00

68.59 5.72 19.98

130 28 C17H19N5 69.62 6.48 23.89

69.58 6.58 23.88

118 87 C18H21N5 70.35 6.84 22.80

70.39 5.78 22.75

174 71 C19H21N5O2 64.95 5.98 19.94

65.04 6.02 20.01

164 67 C22H21N5 74.36 5.91 19.71

74.28 6.09 19.88

185 64 C20H19N7 67.22 5.32 27.45

67.39 5.14 27.61

CP), d

N N-CH3

N N-C2H5

N N-COOC2H5

N N-\_// N-

aRecrystallization from CHQ3/THF.

Scheme 3

2.5. 4-[(4-N,N-Dimethylamino)-2-phenylvinyl)]-6-piperidi-nyl-5-cyano-2-phenyl-pyrimidine (6). A mixture of 6-pip-eridinyl-4-methyl-pyrimidine 4b (0.28 g, 1 mmol) and N,N-dimethylaminobenzaldehyde (0.15 g, 1 mmol) in dioxane (10 mL) in the presence of catalytic amount of piperidine was refluxed for 8h. After cooling, the resulting solid product was collected by filtration and washed with water, and the crude product recrystallized from ethanol/glacial acetic acid to give 0.15 g of pale yellow needles (37% yield), mp 103°C; IR: v 2212 (C=N) cm-1; *H-NMR (CDCl3): S 3.07-2.96, 1.75-1.62 (10H, m, piperidinyl-H), 3.09 (6H, s, CH3), 6.70 (1H, d, J = 2.0 Hz, -CH=), 7.74 (1H, d, J = 2.0 Hz, = CH-), 8.57-8.55, 7.52-7.44 (9H, m, phenyl-H); MS (m/z, %): 409(M+, 100), 381(9), 366(3), 326(5), 289(7), 222(4), 205(6), 195(8), 190(5), 104(7), 85(5). Anal. Calcd. for C26H27N5: C, 76.28; H, 6.60; N, 17.11. Found: C, 76.01; H, 6.42; N, 17.351%.

2.6. 6-Cyanopropylthio-5-cyano-4-methyl-2-phenyl-pyrimi-din (8). A mixture of 5-cyano-1,6-dihydro-4-methyl-2-phenyl-6-thioxopyrimidine 1 (2.27 g, 0.01 mol), sodium ethoxide (1.36 g, 0.02 mol), and 4-chlorobutyronitrile (1.03 g, 0.01 mol) in DMF (50 mL). tte reaction mixture was stirred at room temperature for 4 h and then diluted with cold water (50 mL) was collected by filtration, washed with water, and recrystallized from DMF/ethanol to give 2.88 g of yellow needles (98% yield), mp 144°C; IR: v 2220 (C=N) cm-1; 1H-NMR (CDCl3): S 2.21 (2H, t, J = 2.54 Hz, CH2), 2.58-2.56 (2H, m, CH2), 2.71 (3H, s, CH3), 3.54 (2H, t, J = 2.27 Hz, CH2), 8.47-8.46, 7.55-7.49 (5H, m, phenyl-H); MS (m/z, %): 294(M+,22), 254(60), 241(100), 227(28), 194(9), 153(31), 104(15), 77(16). Anal. Calcd. for C16H14N4S: C, 65.30; H, 4.76; N, 19.04. Found: C, 65.23; H, 4.70; N, 19.13%.

H 1 -N^scH2œ^> 13

Xylene reflux

(CH30)2CHN(CH3)2

CH-N(CH3)2

11 "| n^nh2

~n I 22 H

CH3COOH

reflux -HN(CH3)2

ch3cooh

reflux

Table 2: Spectral data of 6-substituted-pyrimidine derivatives (4a, b and 5a-f).

Compd. MS (m/e M+)

IR (KBr) v (cm-1)

'H-NMRa (CDCl3) 5 (ppm)

4a 264(98), 235(100), 209(30), 10(8). 2204 (C=N) 2.30-2.11 (4H, m, 3,4-H ofpyrrolidinyl), 2.82 (3H, s, CH3), 4.09 (2H, t, J = 1.40 Hz, 5-H ofpyrrolidinyl), 4.21 (2H, t, J = 1.40 Hz, 2-H ofpyrrolidinyl), 8.08-8.01, 1.16-1.51 (5H, m, phenyl-H).

4b 218(100), 263(1), 249(92), 236(26), 223(24), 210(8), 196(12), 154(30), 104(42), 11(11), 55(3). 2208 (C=N) 1.16,4.02 (10H, m, piperidinyl-H), 2.69 (3H, s, CH3), 8.41-8.39,1.50-1.45 (5H, m, phenyl-H).

5a 280(100), 249(32), 236(11), 223(91), 194(16), 153(46), 125(4), 104 (31), 11(24), 56(1). 2210 (C=N) 2.69 (3H, s, CH3), 3.85 (4H, d, J = 1.0 Hz, 2,6-H of morpholinyl), 4.01 (4H, d, J = 1.0 Hz, 3,5-H of morpholinyl), 8.40-8.38, 1.52-1.45 (5H, m, phenyl-H).

5b 293(9), 249(4), 236(19), 223(100), 194(4), 153(11), 104(14), 83(46), 10(43), 55(1). 2205 (C=N) 2.43 (3H, s, CH3), 2.68 (3H, s, N-CH3), 2.66 (4H, d, J = 1.0 Hz, 2,6-H of piperazinyl), 4.14 (4H, d, J = 1.0 Hz, 3,5-H ofpiperazinyl), 8.40-8.38, 1.50-1.45 (5H, m, phenyl-H).

5c 301(12), 263(4), 249(5), 236(29), 223(65), 194(4), 153(11), 104(12), 91(60), 84(100), 12(14), 55(1). 2206 (C=N) 1.14 (3H, t, J = 1.44 Hz, N-CH2CH3), 2.61 (3H, s, CH3), 2.51 (2H, q, J = 2.16 Hz, N-CH2CH3), 2.62 (4H, d, J = 1.0 Hz, 2,6-H of piperazinyl), 4.11 (4H, d, J = 1.0 Hz, 3,5-H of piperazinyl), 8.40-8.38,1.50-1.44 (5H, m, phenyl-H).

5d 351(95), 336(1), 322(8), 306(2), 283(11), 218(2), 249(9), 236(382), 223(100), 194(6), 153(1), 141(10), 58(4). 1105 (C=O) 2201 (c^N) 1.30 (3H, t, J = 1.43 Hz, OCH2CH3), 2.69 (3H, s, CH3), 3.61 (4H, t, J = 1.06 Hz, 2,6-H of piperazinyl), 4.05 (4H, d, J = 1.00 Hz, 3,5-H of piperazinyl), 4.20 (2H, q, J = 2.13 Hz, COOCH2), 8.40-8.38,1.53-1.45 (5H, m, phenyl-H).

5e 355(42), 249(5), 236(28), 223(100), 194(3), 111(4), 153(10), 132(94), 120(31), 104(44), 11(20), 55(5). 2200 (C=N) 2.10 (3H, s, CH3), 3.31 (4H, d, J = 1.09 Hz, 2,6-H of piperazinyl), 4.25 (4H, d, J = 1.00 Hz, 3,5-H of piperazinyl), 8.43-8.42,1.52-6.91 (10H, m, phenyl-H).

5f 351(51), 262(9), 249(15), 236(34), 223(100), 194(5), 119(6), 153(11), 141(44), 134(61), 123(24), 108(39), 103(16), 80(22), 55(5). 2204 (C=N) 2.69 (3H, s, CH3), 4.02 (4H, d, J = 1.06 Hz, 2,6-H of piperazinyl), 4.16 (4H, d, J = 1.06 Hz, 3,5-H of piperazinyl), 6.56 (1H, m, 5-H of pyrimidinyl), 8.36 (2H, d, J = 1.0 Hz, 4,6-H of pyrimidinyl), 8.42-8.40, 1.51-1.45 (5H, m, phenyl-H).

aAbbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet.

2.7. 5-Amino-6-benzoyl-4-methyl-2-phenylthieno[2,3-d]py-rimidine (10). A mixture of 5-cyano-1,6-dihydro-4-methyl-2-phenyl-6-thioxopyrimidine 1 (2.27 g, 0.01 mol), 2-bro-moacetophenone 9 (1.99 g, 0.01 mol), and sodium ethoxide (1.36 g, 0.02 mol) in DMF (50 mL) was stirred at room temperature for 4 h and then diluted with cold water (50 mL). tte resulting solid product was collected by filtration, washed with water, and recrystallized from DMF/ ethanol to give 3.17 g of yellow needles (92% yield), mp 236°C; IR: v 3421, 3288 (NH2), 1663 (C=O) cm-1; JH-NMR (DMSO-d6): 5 2.56 (3H, s, CH3), 3.71 (2H, br, NH2), 8.39-8.37, 7.95-7.72 (10H, m, phenyl-H); MS (m/z, %): 345(M+,100). Anal. Calcd. for C20H15N3OS: C, 69.56; H, 4.34; N, 12.17. Found: C, 69.71; H, 4.50; N, 12.43%.

2.8. 6-Benzoyl-4-methyl-5-(1-pyrrolyl)-2-phenylthieno [2,3-d]pyrimidine (11). A mixture of 5-amino-6-benzoyl-4-methyl-2-phenylthieno[2,3-d]pyrimidine 10 (0.34 g, 1 mmol) and 2,5-dimethoxytetrahydrofuran (0.13 g, 1 mmol), in glacial acetic acid (20 mL) was refluxed for 12 h. After cooling, the resulting solid product was collected by filtration and washed with water, and the crude product recrystallized from ethanol/glacial acetic acid to give 0.18 g of brown needles (46% yield), mp 130°C; IR: v 1663 (C=O) cm-1; *H-NMR (CDCl3): S 2.31 (3H, s, CH3), 6.10 (2H, m, 3,4-H of pyrrolyl), 6.71 32H, m, 2,5-H of pyrrolyl), 8.59-8.57, 7.69-7.31 (10H, m, phenyl-H); MS (m/z, %): 395(M+,100). Anal. Calcd. for C24H17N3OS: C, 72.91; H, 4.30; N, 10.63. Found: C, 73.01; H, 4.42; N3, 10.67%.

3.08 (3H, s)

(1H, d) 8.25-8.23,

7.9-7.58 (1H, m)

7.99 (1H, d)

-1 \ \\ I 11

N (1H, m) N 8.47 (1H, d)

8.25-8.23, 7.9-7.58 (10H, m)

9.71 (1H, s)

3.38 (3H, s)

8.32-8.3,

7.93-7.65 (10H, m)

Figure 4: Structural assignment of typical protons in 16c and 16e by 'HNMR.

CH3 CH3

m/z = 194 m/z = 223

Figure 5

2.9. 5-(1,2,3,4-Tetrazol-1-yl)-6-benzoly-4-methyl-2-phenyl-thieno[2,3-d]pyrimidine (12). A mixture of 5-amino-6-benzoyl-4-methyl-2-phenylthieno[2,3-d]pyrimidine 10 (0.34 g, 1 mmol), sodium azide (0.065 g, 1 mmol), and triethyl orthoformate (8 mL) was refluxed in acetic anhydride (15 mL) for 4h. tte reaction mixture was cooled. tte resulting solid product was collected by filtration and washed with water, and the crude product recrystallized from DMF/glacial acetic acid to give 0.31 g of orange yellow needles (78% yield), mp 196°C; IR: v 1662 (C=O) cm-1; JH-NMR (CF3COOD): S 2.61 (3H, s, CH3), 8.83 (1H, s, 5-H of tetrazoly), 8.64-8.62, 8.21-7.96 (10H, m, phenyl-H); MS (m/z, %): 398(M+,10), 367(13), 344(100), 268(3), 240(10), 211(2), 105(5). Anal. Calcd. for C21H14N6OS: C, 63.31; H, 3.51; N, 21.10. Found: C, 63.45; H, 3.66; N, 21.31%.

2.10. 6-[ (Benzoylmethyl)thio ]-5-cyano-4-methyl-2-phenyl-py-rimidine (13). A mixture of 5-cyano-1,6-dihydro-4-methyl-2-phenyl-6-thioxopyrimidine 1 (2.27 g, 0.01 mol), sodium ethoxide (0.68 g, 0.01 mol), and 2-bromoacetophenone 9

(1.99 g, 0.01 mol) in DMF (50 ml). tte reaction mixture was stirred at room temperature for 4 h and then diluted with cold water (50 mL) was collected by filtration, washed with water, and recrystallized from chlorofrom/ethanol to give 3.1 g of pale yellow needles (90% yield), mp 169°C; IR: v 2220(C=N), 1679 (C=O) cm-1; 1H-NMR (CDCl3): S 2.67 (3H, s, CH3), 4.77 (2H, s, SCH2), 8.11-8.06, 7.70-7.22 (10H, m, phenyl-H); MS (m/z, %): 345(M+,85), 319(15), 312(30), 242(3), 240(30), 134(10), 105(100), 77(4). Anal. Calcd. for C20H15N3OS: C, 69.56; H, 4.34; N, 12.17. Found: C, 69.68; H, 4.40; N3, 12.33%.

2.11. 6-[(4,5,6-Trisubstituted-2-phenyl-pyridin-3-yl)thio]-5-cyano-4-methyl-2-phenyl-pyrimidine (16a-f) General Procedure. A mixture of compound 13 (0.35 g, 1 mmol) and enaminone derivatives 14a-f (1 mmol) and ammonium acetate (2 mmol) was refluxed in glacial acetic acid (10 mL) for 11 h. After cooling, the resulting solid product was collected by filtration, washed with water, and recrystallized from ethanol/glacial acetic acid. tte physical constants and

m/z = 457

m/z = 186

|l I N m/z = 201

Figure 6

spectral data of compounds 16a-f are recorded in Tables 6 and 7.

2.12. 2-[(5-Cyano-4-methyl-2-phenylpyrimidin-6-yl)thio]-3-dimethylamino-l-phenyl-prop-2-en-l-one (17). A mixture of compound 13 (0.35 g, 1 mmol) and N,N-dimethylformamide dimethylacetal (lmmol) was refluxed in xylene (5mL) for 5 h. After cooling, the resulting solid product was collected by filtration, washed with water, and recrystallized from ethanol/glacial acetic acid afforded 0.26 g of yellow crystals (66% yield), mp 185°C; IR: v 2214 (C=N), 1654 (C=O) cm-1; *H-NMR (CF3COOD): S 2.94 (6H, s, N(CH3)), 3.43 (3H, s, CH3), 7.47 (1H, s, =CH-N), 8.27-8.23, 7.81-7.57 (10H, m, phenyl-H); MS (m/z, %): 400(M+,10), 344(100). Anal. Calcd. for C23H20N4OS: C,69.00; H, 5.00; N, 14.00. Found: C, 59.93; H, 5.23.; N, 14.33%.

2.13. 6-[(4-Phenyl-pyrimidin-5-yl)thio]-5-cyano-4-methyl-2-phenyl-pyrimidine (21). A mixture of compound 17 (0.40 g, 1mmol) and formamide/formic acid (1:1, 1 mmol) 20and ammonium acetate (2 mmol) was refluxed for 7h. After cooling, the resulting solid product was collected by filtration, washed with water, and recrystallized from ethanol/glacial acetic acid to give 0.21 g of yellow needles (56% yield), mp

258°C; IR: v2209 (C=N) cm-1; 1H-NMR (CF3COOD): S 3.84 (3H, s, CH3), 8.21 (1H, s, 6-H of pyrimidinyl), 8.26 (1H, s, 2-H of pyrimidinyl), 8.70-8.69, 8.24-8.02 (10H, m, phenyl-H); MS (m/z, %): 381(54), 345(100), 280(16), 256(8), 210(1), 121(2), 105(22), 98(6), 57(4). Anal. Calcd. for C22H15N5S: C, 69.29; H, 3.93; N, 18.37. Found: C, 69.38; H, 4.02; N, 18.44%.

2.14. 6-[(Substituted)thio]-5-cyano-4-methyl-2-phenyl-pyri-midine Derivatives (19, 23, 25, 27 and 29) General Procedure. A mixture of compound 17 (0.40 g, 1 mmol) and phenylhydrazine 18, 2-amino-benzimidazole 22, 5-amino-1H-tetrazole 24, and 5-amino-pyrazoles 26, 28 (1 mmol) in the presence of glacial acetic acid (5 mL) was refluxed for 7 h. After cooling, the resulting solid product was collected by filtration, washed with water, and the crude product recrystallized from DMF/glacial acetic acid.

2.15. 6-[(1,5-Diphenyl-1h-Pyrazol-4-yl)thio]-5-cyano-4-me-thyl-2-phenyl-pyrimidine (19). Yield 38%, mp 240°C; IR: v 2201 (C=N) cm-1; 1H-NMR (CF3COOD): S 3.34 (3H, s, CH3), 7.76 (1H, s, 3-H of pyrazole), 8.25-8.23, 7.81-7.79, 7.70-7.57 (15H, m, phenyl-H); MS (m/z, %): 445(M+,7), 422(6), 355 (4), 344(100), 268(3), 93(2). Anal. Calcd. for C27H19N5S: C, 72.80; H, 4.26; N, 15.73. Found: C, 72.91; H, 4.47; N9, 15.89%.

Table 3: Crystal data and structure refinement for compound 13.

Empirical formula C20H15N3OS

Formula weight 345.41

Temperature 297(2) K

Wavelength 0.71073 Ä

Crystal system Monoclinic

Space group P 21/n

a = 13.5314(9) Ä

a = 90°.

Unit cell dimensions b = 9.5316(6) Ä

ß = 110.7820(10)°.

c = 14.7941(10) Ä

y = 90°

Volume 1783.9(2) Ä3

Density (calculated) 1.286 Mg/m3

Absorption coefficient 0.193 mm-1

F(000) 720

Crystal size 0.67 x 0.63 x 0.46 mm3

"tteta range for data collection 2.60 to 26.01°.

Index ranges -16 < h < 16, -11 < k < 11,

-11 < 1 < 18

Reflections collected 9753

Independent reflections 3499 [R(int) = 0.0305]

Completeness to theta = 26.01° 99.7%

Absorption correction Empirical

Max. and min. transmission 0.9163 and 0.8813

Refinement method Full-matrix least-squares on F2

Data/restraints/parameters 3499/0/226

Goodness-of-fit on F2 1.016

Final R indices [I > 2 sigma(I)] = 0.0478,wß2 = 0.1350

R indices (all data) = 0.0587, = 0.1474

Largest diff. peak and hole -3 0.322 and -0.391 e-Ä

2.16. 6-[(4-Phenyl-benzimidazolo[1,2-a]pyrimidinyl-3-yl) thio]-5-cyano-4-methyl-2- phenyl-pyrimidine (23). Yield 54%, mp 232°C; IR: v 2204 (C=N) (C=N) cm-1; JH-NMR (CF3COOD): 5 2.51 (3H, s, CH3), 8.53 (1H, s, 2-H of benzimidazolo- pyrimidinyl), 8.09-8.08, 7.98-7.86 (14H, m, benzimidazolyl-H and phenyl-H); MS (m/z, %): 470(11), 430(2), 367(2), 355(30), 345(100), 276(2), 227(8), 105(4). Anal. Calcd. for C28H18N6S: C, 71.48; H, 3.82; N, 17.87. Found: C, 71.39; H, 3.99; N, 17.98%.

2.17. 6-[(4-Phenyl-1,2,3,4-tetrazolo[1,5-a]pyrimidinyl-3-yl)thio]-5-cyano-4-methyl-2-phenyl-pyrimidine (25). Yield 50%, mp 233°C; IR: v 2206 (C=N) cm-1; 1H-NMR (CF3COOD): 5 2.63 (3H, s, CH3), 8.65 (1H, s, 2-H of tetrazolopyrimidinyl), 8.22-8.17, 8.11-7.99 (10H, m, phenyl-H); MS (m/z, %): 422(6), 344(100), 292(2), 212(5), 105(3). Anal. Calcd. for C22H14N8S: C, 62.55; H, 3.32; N, 26.54. Found: C, 62.74; H, 3.45; N, 26.66%.

2.18. 6-[(5-Cyano-6-methyl-2-phenylpyrimidin-4-yl)thio]-2-methyl-3-phenylazo-7-phenyl-pyrazolo[1,5-a]pyrimidine (27). Yield 67%, mp 230°C; IR: v 2200 (C=N) cm-1 1H-NMR (CF3COOD): S 2.62 (3H, s, CH3), 2.91 (3H, s CH3), 8.00 (1H, s, 5-H of pyrazolopyrimidinyl), 8.28-8.27 7.84-7.61 (15H, m, phenyl-H); MS (m/z, %): 538(15) 461(8), 344(100), 316(10), 240(4), 182(1), 124(1), 93(2) Anal. Calcd. for C31H22N8S: C, 69.14; H, 4.08; N, 20.81 Found: C, 69.26; H, 4.22; N, 20.66%.

2.19. 7-[(5-Cyano-6-methyl-2-phenylpyrimidin-4-yl)thio]-4-methyl-2,8-diphenyl-pyrimido[4 ,5 :3,4]pyrazolo[1,5-a]pyrimidine (29). Yield 65%, mp 289°C; IR: v 2201 (C=N) cm-1; 1H-NMR (CF3COOD): S 2.37 (3H, s, CH3), 3.52 (3H, s, CH3), 7.67 (1H, s, 6-H of pyrimidopyrazolopyrimidinyl), 8.41-8.39, 7.95-7.72 (15H, m, phenyl-H); MS (m/z, %): 562(15), 460(1), 418(2), 316(10), 368(100), 344(20), 249(4), 225(16), 197(10), 153(12), 104(13), 77(17), 51(4). Anal. Calcd. for C33H22N8S: C, 70.46; H, 3.91; N, 19.92. Found: C, 70.66; H, 4.12; N2^0.16%.

2.20. X-Ray Structure Study of Compound 13. tte diffraction data of compound 13 was collected on a Siemens CCD diffractometer, which was equipped with graphite-monochromated Mo-Ka (Ka = 0.71073 A) radiation. Data reduction was carried by standard methods with use of well-established computational procedures [28,29]. A pale yellow crystal of compound 13 was mounted on the top of a glass fiber with epoxy cement. tte hemisphere data collection method was used to scan the data points at 3.34 < 20 < 52.02°. tte structure factors were obtained after Lorentz and polarization correction. tte final residuals of the final refinement were R1 = 0.0478, wR2 = 0.1350. tte crystallographic data of compound 13 has been deposited with the Cambridge Crystallographic Data Center as supplementary publication no. CCDC 752301. Copy of this information maybe obtained free of charge via http://www.ccdc.cam.ac.uk or from tte Director, CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (fax: +441223/336-033; email: deposit@ccdc.cam.ac.uk).

3. Results and Discussion

All relevant reactions are depicted in Schemes 1, 2, 3, and

4. tte required compound 5-cyano-1,6-dihydro-4-methyl-2-phenyl-6-thioxopyrimidine 1 was prepared by treating ben-zoylisothiocyanate with 3-aminocrotononitrile in refluxing dioxane [26]. Several pyrimidines substituted at position-6 with different heterocyclic residues were obtained via treatment of thioxopyrimidine 1 with different reagents. ttus, reaction of thioxopyrimidine 1 with methyl iodide in the presence of sodium methoxide to yield the 6-methylthio-4-methyl-2-phenyl-pyrimidine 2, which reacted with selenium oxide in dioxane afforded the 4-formyl-6-methylthio-2-phenyl-pyrimidine 3 (Scheme 1). tte IR spectra of compound 3 showed the characteristic absorption bands at 1689 cm- for the HC=O group and 2218 cm- for

Table 4: Selected bond lengths [A] and angles [°] forcompound 13a.

S-C(10) 1.743(17)

O-C(14) 1.209(2)

N(1)-C(7) 1.341(2)

N(2)-C(7) 1.339(2)

C(1)-C(6) 1.383(3)

C(6)-C(7) 1.481(2)

C(9)-C(10) 1.401(2)

N(6)-C(12) 1.423(3)

C(14)-C(15) 1.482(3)

C(10)-S-C(13) 100.0(9)

C(10)-N(2)-C(7) 117.0(13)

N(1)-C(7)-C(6) 117.3(15)

C(8)-C(9)-C(10) 118.0(14)

N(2)-C(10)-S 119.6(12)

O-C(14)-C(15) 122.1(19)

C(15)-C(14)-C(13) 116.3(17)

C(16)-C(15)-C(14) 122.8(2)

S-C(13) 1.784(2)

N(1)-C(8) 1.335(2)

N(2)-C(10) 1.334(19)

N(3)-C(12) 1.135(3)

C(5)-C(6) 1.389(3)

C(8)-C(9) 1.387(3)

C(13)-C(14) 1.523(3)

C(13)-C(14) 1.349(5)

C(15)-C(16) 1.393(3)

C(8)-N(1)-C(7) 117.4(15)

N(1)-C(7)-N(2) 125.7(14)

N(2)-C(7)-C(6) 116.8(14)

N(2)-C(10)-C(9) 120.9(15)

C(9)-C(10)-S 119.3(12)

O-C(14)-C(13) 121.4(19)

C(16)-C(15)-C(20) 118.6(2)

C(20)-C(15)-C(14) 118.6(2)

aStandard deviations in parentheses.

the C=N group. In addition, the JH NMR spectra (DMSO-d6) of compound 3 revealed two singlets at S 2.74 (3H, s) and 9.85 (1H, s), which were readily assigned to the SCH3 and HC=O groups, respectively. On the other hand, a series of novel 6-substituted-pyrimidine derivatives 4a,b and 5a-f were also obtained by the condensation reaction of compound 2 with appropriate secondary amines such as pyrrolidine, piperidine, morpholine, N-methylpiperazine, N-ethylpiperazine, ethyl 1-piperazinecarboxylate, 1-phenyl-piperazine and 1-(2-pyrimidyl)piperazine, (Scheme 1). Compounds 4a,b and 5a-f were obtained generally in 28-89% yields. tte structures of 4a,b and 5a-f were verified by elemental analysis and by spectroscopic methods. Physical and spectral data of compounds 4a,b and 5a-f are recorded in Tables 1 and 2, respectively. Typical assignments for 5f by

*H-NMR are shown in Figure 1. ttese structures get further support from mass spectroscopy. tte mass fragmentation pattern of compound 5d showed the presence of the ion peaks [M-CH3]+ at m/z 336, [M-CH2CH3]+at m/z 322, [M-OCH2CH3]+ at m/z 306 and [M-COOCH2CH3]+ at m/z 278. Also, it has been observed that electron impact (EI) spectral has many common features. Compounds 5a-f exhibited m/z 249, m/z 236, m/z 223, m/z 194 and m/z 153 piece peaks. tte possible mass fragmentation pathways of compounds 5a-f are shown in Figure 5.

Next, treatment of 6-piperidinyl-4-methyl-pyrimidine 4b with N,N-dimethyl-aminobenzaldehyde in refluxing dioxane in the presence of catalytic amount of piperidine yielded the 4-[(4-N,N-dimethylamino)-2-phenylvinyl)]-6-piperidinyl-5-cyano-2-phenyl-pyrimidine 6. tte *H-NMR spectra (CDCl3) of compound 6 revealed a sharp singlet at S 3.09 (6H, s) assigned to the -N(CH3)2 protons and at S 6.70 (1H, d) and 7.74 (1H, d) assigned to the -CH=CH- of 4-dimethylaminophenylethylene moiety, two multiplets at S 3.07-2.96, 1.75-1.62 (10H, m) assigned to the piperidinyl protons and a multiplet at S 8.57-7.44 (9H, m) assigned to the phenyl protons, were also confirmed by the mass spectrum m/z 409(M+). However, reaction of compound 2 with benzhydrazide did not produce the desired compound 7, but led only to the recovery of starting material. On the other hand, the 6-cyanopropylthio-pyrimidine 8 was also obtained by treatment of compound 1 with 4-chlorobutyronitrile in DMF at room temperature in the presence of sodium ethoxide in a molar ratio of 1: 2 (Scheme 2). Nevertheless, under same reaction conditions, treatment of compound 1 with 2-bromoacetophenone 9 formed the nonisolable S-alkylated intermediate, which via nucleophilic substitution and intramolecular cyclocondensation afforded the corresponding 5-amino-6-benzoly-4-methyl-2-phenylthieno[2,3-d]pyrimidine 10, which when reacted with 2,5-dimethoxy-tetrahydrofuran in glacial acetic acid produced the 5-(1-pyrrolyl)-6-benzoly-4-methyl-2-phenylthieno[2,3-d]pyrimidine 11. Also, reaction of compound 10 with sodium azide and triethyl orthoformate in acetic anhydride afforded the corresponding 5-(1,2,3,4-tetrazol-1-yl)-6-benzoly-2-phenyl-thieno[2,3-d]pyrimidine 12 (Scheme 2). tte structure of compounds 10-12 was established on the basis of their elemental analysis and spectral data. tte IR spectra of compounds 11 and 12 indicated the complete disappearance of NH2 and showed the characteristic absorption band at 1663-1662 cm- for the C=O group. tte H-NMR spectra (CDCl3) of compound 11 revealed two multiplets at S 6.10 (2H, m) and 6.71 (2H, m), which were readily assigned to the hydrogen of the pyrrolyl ring. Moreover, compound 12 showed a singlet at S 8.83 (1H, s) assigned to the hydrogen attached at C5 of the tetrazolyl ring.

On the other hand, treatment of compound 1 with 2-bromoacetophenone 9 in the presence of sodium ethoxide in a molar ratio of 1:1 afforded the open-chain product 6-(benzoylmethyl)thio-2-phenyl-pyrimidine 13 in 90% yield (Scheme 2). tte IR spectra of compound 13 indicated the characteristic absorption bands at 1679 cm- for the C=O

Table 5: Selected torsion angles for compound 13.

C(13)-S-C(10)-N(2) -16.1°

C(13)-S-C(10)-C(9) 165.5°

C(1)-C(6)-C(7)-N(2) -175.1°

C(1)-C(6)-C(7)-N(1) -175.1°

C(16)-C(15)-C(14)-O 165.7°

C(20)-C(15)-C(14)-O -14.1°

C(13)-C(14)-C(15)-C(16) -13.2°

C(13)-C(14)-C(15)-C(20) 167.0°

S-C(13)-C(14)-O 11.3°

S-C(13)-C(14)-C(15) -169.7°

group and 2220 cm 1 for the C=N group. In particular, the XH-NMR spectrum (CDCl3) of compound 13 revealed a singlet at S 4.77 (2H, s) assigned to the SCH2CO protons. tte structure of 13 was unambiguously confirmed by X-ray crystallography. tte suitable single crystals of compound 13 were obtained by slow crystallization from chloroform/DMF at room temperature. Perspective view and the numbering of the atoms are depicted in Figure 2. ttis drawing clearly establishes the structural formula and also shows the conformation of the molecule. tte packing diagram (Figure 3) in the solid state by intermolecular hydrogen bonding between C-H of the -S-CH2 group and C=O atom (C-H—O = 2.261 Á, zC—H—O = 145.5°). tte relevant crystallographic date and structure refinement are recorded in Table 3. tte selected bond lengths and bond angles are listed in Table 4. tte hydrogen atoms were refined isotropically in idealized positions riding on the atom to which they are attached. tte crystal system of compound 13 is monoclinic, the space group is P 21/n and data was collected in the range 2.60 to 26.01°. Details of the intensity collection are recorded in Table 3.

tte basal plane is formed by phenyl(C(15))-carbony-lmethylthio(C(14)), carbonylmethylthio-pyrimidine(C(10)), and pyrimidine(C(7))-phenyl(C(6)) atoms, with bond lengths of 1.482(3), 1.7436(17), and 1.481(2) Á, respectively. tte phenyl ring is in the cis (Z) configuration with respect to the S atom and the fused pyrimidine system (Figure 2). Moreover, the fused pyrimidine system is almost planar and due to the effect of carbonylmethyl-S moiety the phenyl group exhibit noticeable quinoid character that is demonstrated by theshortening ofthe C(17)-C(18) [1.353(5) Á], C(18)-C(19) [1.383(5) Á], C(19)-C(20) [1.385(4) Á], and c(16)-c(17) [1.374(3) Á] bond lengths compared to the standard Car-Car distance of 1.397(1) Á [30]. In addition, the C(16)-C(17) phenyl and carbonyl group are in a staggered conformation with respect to the O atom giving rise to angular distortion at C(15) and C(14) [C(16)-C(15)-C(14)C(20)-C(15)-C(14)] (Table 4). tte S-C(10) [1.7436(17) Á] bond is longer than the C(6)-C(7)[1.481(2) Á], which is probably due to electron withdrawing effect of the S atom. Also, the interesting torsion angles which entirely define the molecule conformation are selected and listed in Table 5. Moreover, the C(9)-C(10) [1.401(2) Á] and N(1)-C(7) [1.341(2) Á] bonds are longer

than the N(2)-C(10) [1.334(19) A]. tte C(1)-C(2) phenyl ring has a dihedral angle with N(2)-C(10) pyrimidine ring of 171.1°, while the carbonylmethylthio's dihedral angle with this pyrimidine is 101.0°. Furthermore, the C(16)-C(17) phenyl ring attached to the carbonylmethyl group and makes a dihedral angle of 112.2° with pyrimidine ring plane and the C(16)-C(17) phenyl ring has a dihedral angle with carbonylmethylthio group of 15.7°.

On the other hand, the reaction of compound 13 with enaminone derivatives 14a-f was also investigated. ttus, it has been found that compound 13 with 3-dimethylamino-1-(phenyl)prop-2-enone 14a in refluxing glacial acetic acid in the presence of excess ammonium acetate gave a yellow product of molecular formula C29H20N4S (55% yield, mp 218°C). Spectroscopic analyses revealed that 6-[(2,6-diphenyl-pyridin-3-yl)thio]-5-cyano-4-methyl-2-phenylpyrimidine 16a was obtained (Scheme 3). tte IR spectra of the reaction product indicated the absence of the C=O group and showed the characteristic absorption band at 2203 cm-1 for the C=N group. tte XH-NMR spectra (CF3COOD) of the reaction product showed additional two doublets at S 8.44 (1H, d) and 8.76 (1H, d) assigned to the hydrogen attached at C5 and C4 of pyridine moiety, respectively, and at S 8.54-8.52, 8.19-7.87 (15H, m) assigned to the phenyl protons. tte structure of compound 16a was further confirmed by mass spectrum (m/z 456 (M+)). tte formation of compound 16a would involve an initial nucleophilic substitution of the exocyclic methylene group in compound 13 to the activated double bond in enaminone 14a to form the intermediate 15, which then undergoes amination and intramolecular cyclization via loss of water affording the final product 16a. Similarly, treatment of compound 13 with enaminone derivatives 14b-f, under similar reaction conditions, afforded the corresponding 6-[(4,5,6-trisubstituted-2-phenyl-pyridin-3-yl)thio]-5-cyano-4-methyl-2-phenyl-pyri-midines 16b-f (Scheme 3). Typical assignments for 16c and 16e by 1H-NMR are shown in Figure 4. tte physical constants and spectral data of compounds 16a-f are recorded in Tables 6 and 7. ttese structures get further support from mass spectroscopy. tte possible mass fragmentation pathway of compounds 16c is shown in Figure 6.

Furthermore, treatment of 6-(benzoylmethyl)thio-pyrimidine 13 with N,N-dimethylformamide dimethylacetal (DMFDMA) gave the enaminone derivative 2-[(5-cyano-4-methyl-2-phenylpyrimidin-6-yl)thio]-3-dimethylamino-1-phenylprop-2-en-1-one 17(Scheme 4). tte 1H NMR spectra (CF3COOD) of compound 17 revealed a sharp singlet at S 2.94 (6H, s) assigned to the -N(CH3)2 protons and at S 7.47 (1H, s) assigned to the -C=CH-N, was also confirmed by the mass spectrum m/z 400 (M+). On the other hand, the study was extended to investigate the behavior of enaminone derivative 17 with different nucleophiles like amino compounds with a view to synthesizing various heterocyclic ring systems. Intramolecular cyclization of enaminone derivative 17 gave different products depending on reaction reagents. ttus, treatment of enaminone derivative 17 with phenylhydrazine 18 in the presence

Table 6: Physical and analytical data of 6-[(4,5,6-trisubstituted-2-phenyl-pyridin-3-yl)thio]-5-cyano-4-methyl-2-phenyl-pyrimidine derivatives (16a-f).

'CN R"

Compd. R r' II R M.P. (°C)a Yield (%) Molecular formula Elemental C analysis (%) Calcd/Found. H N

16a 0 H H 218 55 C29H20N4S 76.31 76.44 4.38 4.49 12.28 12.24

16b H H 203 41 C27H18N4S2 70.12 70.31 3.89 3.94 12.12 12.16

16c 0 H H 217 50 C28H19N5S 73.52 73.59 4.15 4.29 15.31 15.55

16d 0 CN H 200 47 C30H19N5S 74.84 74.65 3.95 4.02 14.55 14.68

16e H CH3 205 48 C28H20N4S2 70.58 70.66 4.20 4.48 11.76 11.84

16f CH3 co^t) H 230 46 C31H22N4OS 74.69 74.88 4.41 4.52 11.24 11.36

aRecrystallization from CH3COOH/DMF.

Table 7: Spectral data of 6-[(4,5,6-trisubstituted-2-phenyl-pyridin-3-yl)thio]-5-cyano-4-methyl-2-phenyl-pyrimidine derivatives (16a-f).

Compd. MS (m/e M+)

IR (KBr) v (cm-1)

'H-NMRa (CF3COOD) ^ (ppm)

456(6), 354(48), 344(100), 328(1), 268(3), 25l(l5), 236(l), 186(2), 105(3).

462(5), 435(10), 430(6), 354(18), 344(100), 16b 268(2), 251(6), 185(3), 171(4), 143(7),

129(3).

457(4), 430(9), 368(3), 354(100), 344(90), 303(8), 268(20), 251(45), 201(3), 186(7), 105(10).

481(4), 454(28), 430(55), 378(4), 354(100), 347(86), 303(20), 267(46), 201(4), 137(14) 105(21), 77(4).

476(5), 430(10), 368(55), 344(100), 327(4), 268(8), 265(18), 201(2), 105(2).

498(5), 430(3), 368(7), 344(100), 268(5), 201(2), 105(2), 77(2).

2203 (C=N)

2206 (C=N)

2208 (C=N)

2210 (C=N)

2206 (C=N)

1688 (C=O) 2207 (C^N)

3.67 (3H, s, CH3), 8.44 (1H, d, J = 1.01 Hz, 5-H of pyridyl), 8.76 (1H, d, J = 1.01 Hz, 4-H of pyridyl), 8.54-8.52, 8.19-7.87 (15H, m, phenyl-H).

3.63 (3H, s, CH3), 8.36 (1H, d, J = 1.00 Hz, 5-H of pyridyl), 8.68 (1H, d, J = 1.00 Hz, 4-H of pyridyl), 8.20 (1H, d, J = 1.00 Hz, 3-H ofthienyl-H)„ 8.45 (1H, d, J = 1.00 Hz, 5-H ofthienyl-H), 8.47-8.45, 8.13-7.80 (11H, m, 4-H of thienyl-H and phenyl-H).

3.08 (3H, s, CH3), 7.99 (1H, d, J = 1.00 Hz, 4-H of pyridyl), 8.15 (1H, d, J = 1.00 Hz, 4-H of S-pyridyl), 8.25-8.23, 7.90-7.58 (12H, m, 5-H of S-pyridyl, 5-H of pyridyl and phenyl-H), 8.47 (1H, d, J = 1.00 Hz, 6-H of pyridyl), 9.79 (1H, s, 2-H of pyridyl).

3.02 (3H, s, CH3), 8.55 (1H, s, 4-H of pyridyl), 8.32-8.30, 7.79-7.65 (15H, m, phenyl-H).

2.30 (3H, s, CH3), 3.38 (3H, s, CH3), 7.81 (1H, s, 5-H of pyridyl), 8.04 (1H, dd, J = 1.53, 1.51 Hz, 4-H of thienyl-H), 8.15 (1H, d, J = 1.00, Hz, 3-H ofthienyl-H), 8.52 (1H, d, J = 1.00, Hz, 5-H ofthienyl-H), 8.32-8.30, 7.93-7.65 (10H, m, phenyl-H).

2.32 (3H, s, CH3), 2.82 (3H, s, CH3), 8.84 (1H, s, 4-H of pyridyl), 8.41-8.36, 8.30-8.17 (15H, m, phenyl-H).

aAbbreviations: s: singlet; d: doublet; m: multiplet.

of glacial acetic acid afforded the 6-[(1,5-diphenyl-1H-pyrazol-4-yl)thio]-pyrimidine 19 (Scheme 4). tte structure of pyrazole derivative 19 was established on the basis of their elemental analysis and spectral data. tte IR spectra of compound 19 indicated the absence of the C=O group and showed the characteristic absorption bands at 2201cm-1 for the C=N group. tte 1H-NMR spectra (CF3COOD) of compound 19 revealed a sharp singlet at S 7.76 (1H, s) assigned to the hydrogen attached at C3 of pyrazole ring and at S 8.25-8.23, 7.81-7.79, 7.70-7.57 (15H, m) assigned to the phenyl protons, which was also confirmed by the mass spectrum m/z 445 (M+). tte formation of compound 19 would involve an initial nucleophilic substitution of the amino group in phenylhydrazine 18 to the activated double bond in enaminone derivative 17, followed by deamination, to form the intermediate 19', which then undergoes intramolecule cyclization via loss of water [31] affording the final product 19. Next, the bis-pyrimidine derivative 6-[(4-phenyl-pyrimidin-5-yl)thio]-5-cyano-4-methyl-2-phenyl-pyrimidine 21 was also obtained by the intramolecular cyclization of compound 17 with formamide/formic acid in the presence of excess ammonium acetate. tte 1H-NMR spectra (CF3COOD) of compound 21 revealed additional two sharp singlets at S 8.21 (1H, s) and 8.26 (1H, s) assigned to the hydrogen attached at C6 and C2 of pyrimidine ring and at S 8.70-8.69, 8.24-8.02 (10H, m2! assigned to the phenyl protons, which was also confirmed by the mass spectrum m/z 381 (M+).

Finally, intramolecular cyclization of the enaminone derivative 17 with 2-amino-bezimidazole 22, 5-amino-1H-tetrazole 24, 3-amino-4-phenylazo-pyrazole 26 and 3-amino-4-methyl-6-phenyl-pyrazolo[3,4-d]pyrimidine 28 under acid conditions afforded the corresponding ben-zimidazolo[1,2-a]pyrimidine 23, 1,2,3,4-tetrazolo[1,5-a] pyrimidine 25, azopyrazolo[1,5-a]pyrimidine 27, and pyrimido-[4 ,5 : 3,4]pyrazolo[1,5-a]pyrimidine 29, respectively (Scheme 4). tte mechanisms of compounds 23, 25, 27, and 29 are similar to compound 19. tte structures of compounds 23, 25, 27, and 29 were established on the basis of their elemental analysis and spectral data. For instance, the 1H NMR spectra of compounds 23 and 27 revealed a sharp singlet at S 8.53 (1H, s) and at S 8.00 (1H, s), which assigned to the hydrogen attached at C2 of benzimidazolopyrimidine and at C5 of pyrazolopyrimidine ring, respectively.

4. Conclusion

In conclusion, 6-methylthio-pyrimidine 2, 6-(benzoyl-methyl) thio-pyrimidine 13 and 2-[(5-cyano-4-methyl-2-phenylpyrimidin-6-yl)thio]-3-dimethylamino-1-pheny-lprop-2-en-1-one 17 have been shown to be a useful building block for the synthesis of some new N-cycloalkanes, morpholine, piperazines, pyridines, pyrazole, pyrimidine, benzimidazolo[1,2-a]pyrimidine, 1,2,3,4-tetrazolo[1,5-a] pyrimidine, azopyrazolo[1,5-a]pyrimidine, and pyrimido [4 ,5 : 3,4]pyrazolo[1,5-a]pyrimidine, respectively. tte structure of all newly synthesized compounds was established

from their spectral data, elemental analysis, and the X-ray crystal analysis.

Acknowledgments

tte authors are grateful to the highly valued instrument cent of National Taiwan Normal University for measuring the data of spectroscopy. ttey also want to thank National Science Council of Taiwan (NSC 97-2113-M-253-001) for their financial support.

References

[1] K. M. Amin, M. M. Hanna, H. E. Abo-Youssef, F. Riham, and R. F. George, "Synthesis, analgesic and anti-inflammatory activities evaluation of some bi-, tri- and tetracyclic condensed pyrimidines," European Journal of Medicinal Chemistry, vol. 44, no. 11, pp. 4572-4584, 2009.

[2] D. C. Kim, Y. R. Lee, B. S. Yang et al., "Synthesis and biological evaluations ofpyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors," European Journal of Medicinal Chemistry, vol. 38, no. 5, pp. 525-532, 2003.

[3] S. Pandey, S. N. Suryawanshi, Suman Gupta, and V. M. L. Srivastava, "Synthesis and antileishmanial profile of some novel terpenyl pyrimidines," European Journal of Medicinal Chemistry, vol. 39, no. 11, pp. 969-973, 2004.

[4] D. A. Abou El Ella, M. M. Ghorab, E. Noaman, H. I. Heiba, and A. I. Khalil, "Molecular modeling study and synthesis of novel pyrrolo[2,3-d]pyrimidines and pyrrolotriazolopyrimidines of expected antitumor and radioprotective activities," Bioorganic and Medicinal Chemistry, vol. 16, no. 5, pp. 2391-2402, 2008.

[5] Q. Xueqi, B. L. Bokai, W. Qi, L. Deshui, and L. Xian-Fu, "Facile synthesis of novel mutual derivatives of nucleosides and pyrimidines by regioselectively chemo-enzymatic protocol," Bioorganic and Medicinal Chemistry, vol. 16, no. 9, pp. 5181-5188,2008.

[6] D. A. Ibrahim and A. M. El-Metwally, "Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors," European Journal of Medicinal Chemistry, vol. 45, no. 3, pp. 1158-1166, 2010.

[7] L. F. Kuyper, J. M. Garvey, D. P. Baccanari, J. N. Champness, D. K. Stammers, and C. R. Beddell, "Pyrrolo[2,3-d]pyrimidines and pyrido[2,3-d]pyrimidines as conformationally restricted analogues of the antibacterial agent trimethoprim," Bioorganic and Medicinal Chemistry, vol. 4, no. 4, pp. 593-602, 1996.

[8] S. N. Sriharsha, S. Satish, S. Shashikanth, and K. A. Raveesha, "Design, synthesis and antibacterial activity of novel 1,3-thiazolidine pyrimidine nucleoside analogues," Bioorganic and Medicinal Chemistry, vol. 14, no. 22, pp. 7476-7481, 2006.

[9] A. Padmaja, T. Payani, G. D. Reddy, G. Dinneswara Reddy, and V. Padmavathi, "Synthesis, antimicrobial and antioxidant activities of substituted pyrazoles, isoxazoles, pyrimidine and thioxopyrimidine derivatives," European Journal of Medicinal Chemistry, vol. 44, no. 11, pp. 4557-4566, 2009.

[10] B. Ramesh and C. M. Bhalgat, "Novel dihydropyrimidines and its pyrazole derivatives: synthesis and pharmacological screening," European Journal of Medicinal Chemistry, vol. 46, no. 5, pp. 1882-1891,2011.

[11] E. A. Meade, M. Sznaidman, G. T. Pollard, L. M. Beauchamp, and J. L. Howard, "Anxiolytic activity of analogues of 4-benzylamino-2-methyl-7H- pyrrolo[2,3-d]pyrimidines," European Journal of Medicinal Chemistry, vol. 33, no. 5, pp. 363-374,

[12] J. Y. Kim, D. Kim, S. Y. Kang et al., "Arylpiperazine-containing pyrimidine 4-carboxamide derivatives targeting serotonin 5-HT2A, 5-HT2C, and the serotonin transporter as a potential antidepressant," Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 22, pp. 6439-6442, 2010.

[13] E. P. D. S. Falcaoa, S. J. de Melo, R. M. Srivastava, M. T. J. D. A. Catanho, and S. C. Do Nascimento, "Synthesis and antiinflammatory activity of 4-amino-2-aryl-5-cyano-6-3- and

4-(N-phthalimidophenyl) pyrimidines," European Journal of Medicinal Chemistry, vol. 41, no. 2, pp. 276-282, 2006.

[14] K. S. Gudmundsson, B. A. Johns, and J. Weatherhead, "Pyra-zolopyrimidines and pyrazolotriazines with potent activity against herpesviruses," Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 19, pp. 5689-5692, 2009.

[15] M. P. Clark, K. M. George, R. G. Bookland et al. et al., "Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)," Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 5, pp. 1250-1253, 2007.

[16] N. Kumar, A. Chauhan, and S. Drabu, "Synthesis of cyanopyri-dine and pyrimidine analogues as new anti-inflammatory and antimicrobial agents," Biomedicine and Pharmacotherapy, vol. 65, no. 5, pp. 375-380,2011.

[17] J. M. Quintela, C. Peinador, L. González et al., "6-Dimethylamino 1H-pyrazolo[3,4-d]pyrimidine derivatives as new inhibitors of inflammatory mediators in intact cells," Bioorganic and Medicinal Chemistry, vol. 11, no. 6, pp. 863-868, 2003.

[18] B. Tozkoparan, M. Ertan, P. Kelicen, and R. Demirdamar, "Synthesis and anti-inflammatory activities of some thiazolo[3,2-a]pyrimidine derivatives," Farmaco, vol. 54, no. 9, pp. 588-593,

[19] J. P. Zhou, Y. W. Ding, H. B. Zhang, L. Xu, and Y. Dai, "Synthesis and anti-inflammatory activity of imidazo[1,2-a]pyrimidine derivatives," Chinese Chemical Letters, vol. 19, no. 6, pp. 669-672, 2008.

[20] H. S. Choi, Z. Wang, W. Richmond et al. et al., "Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2," Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 10, pp. 2689-2692, 2006.

[21] I. Devesa, M. J. Alcaraz, R. Riguera, and M. L. Ferrándiz, "A new pyrazolo pyrimidine derivative inhibitor of cyclooxygenase-2 with anti-angiogenic activity," European Journal of Pharmacology, vol. 488, no. 1-3, pp. 225-230, 2004.

[22] S. M. Sondhi, N. Singh, M. Johar, and A. Kumar, "Synthesis, anti-inflammatory and analgesic activities evaluation of some mono, bi and tricyclic pyrimidine derivatives," Bioorganic and Medicinal Chemistry, vol. 13, no. 22, pp. 6158-6166, 2005.

[23] Y. W. Ho and W. H. Yao, "Reactions of 6-acetyl-4-methyl-

5-(1-pyrrolyl)-2-phenylthieno-[2,3-d] pyrimidine in heterocyclic synthesis: Convenient route to some Schiff's bases, chalcones, pyridines, pyridin-2(1H)-ones and 2H-pyran-2-one derivatives incorporating a 5-(1-pyrrolyl)-2-phenylthieno[2,3-d]pyrimidine moiety," Journal of the Chinese Chemical Society, vol. 52, no. 2, pp. 313-325, 2005.

[24] Y. W. Ho, "5-(1-Pyrrolyl)-2-phenylthieno[2,3-d]pyrimidine as building block in heterocyclic synthesis: Novel synthesis of some pyrazoles, pyrimidines, imidazo[1,2-a]pyrimidines,

pyrazolo[1,5-a]pyrimidines, pyrido-(pyrimido) pyrazolo[1,5-a]pyrimidines, 1,2,4-triazolo[1,5-a]pyrimidine and a 1,2,3,4-tetrazolo[1,5-a]pyrimidine derivative," Journal of the Chinese Chemical Society, vol. 54, no. 4, pp. 1075-1085, 2007.

[25] Y. W. Ho and M. C. Suen, "Synthesis and structure of novel thieno[2,3-d]pyrimidine derivatives containing 1,3,4-oxadiazole moiety," Journal of the Chinese Chemical Society, vol. 56, no. 2, pp. 408-415, 2009.

[26] Y. W. Ho and C. T. Yao, "Synthesis of some new 6,8-disubstituted 7,8-dihydropyrimido[2,3:4,3] pyrazolo[1,5-a] pyrimidines and 6,7,8-trisubstituted pyrimido [2,3:4,3]pyra-zolo[1, 5-a]pyrimidine derivatives," Journal of the Chinese Chemical Society, vol. 50, no. 2, pp. 283-296, 2003.

[27] F. Karci and A. Demir^ali, "Synthesis of disazo pyrazolo[1,5-a]pyrimidines," Dyes and Pigments, vol. 74, no. 2, pp. 288-297, 2007.

[28] XSCANS, Release, 2.1, Siemens Energy & Automation, Inc, Madison, Wis, USA, 1995.

[29] SMART/SAINT/ASTRO, Release, 4.03, Siemens Energy & Automation, Inc, Madison, Wis, USA, 1995.

[30] L. Roman, V. Olena, H. Serhiy, Z. Lucjusz, and G. Andrej, "New 5-substituted thiazolo[3,2-fo][1,2,4]triazol-6-ones: synthesis and anticancer evaluation," European Journal of Medicinal Chemistry, vol. 42, no. 5, pp. 641-648, 2007.

[31] K. M. Dawood, A. M. Farag, and E. A. Ragab, "A facile access to polysubstituted bipyrazoles and pyrazolylpyrimidines," Journal of the Chinese Chemical Society, vol. 51, no. 4, pp. 853-857,2004.

Copyright of Journal of Chemistry is the property of Hindawi Publishing Corporation and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.